Method Of Synchronizing Cell Division Patents (Class 435/376)
  • Patent number: 9439949
    Abstract: The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (PRP), the growth factors having increased weight.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: September 13, 2016
    Assignee: Gray Reed & McGraw, P.C.
    Inventors: James Bennie Gandy, Jeri Gandy
  • Patent number: 8829160
    Abstract: An isolated antibody that has a specific binding affinity to a polypeptide comprising the amino acid sequence HTEGKP (SEQ ID NO: 2) phosphorylated at threonine is provided. The antibody may be used as biomarker for mitotic cells. A method for using the antibody in accordance with the invention comprises contacting a cell with the antibody and detecting antibody bound to the cell as an indicator of the cell being in the mitotic state. A reagent kit comprising the antibody is also provided.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: September 9, 2014
    Assignee: The Florida State University Research Foundation, Inc.
    Inventors: Myra Hurt, Raed Rizkallah
  • Patent number: 8685730
    Abstract: Methods and devices for culturing human pluripotent stem cells to produce cells of the pancreatic lineage are disclosed. The methods include steps of culturing the stem cells under conditions that induce the expression of mesendoderm/primitive streak and definitive endoderm markers in a chemically defined medium including an effective amount of i) fibroblast growth factor, ii) Activin A, and iii) bone morphogenetic protein. The methods further include the steps of culturing cells under conditions favoring the formation of at least one of intact embryoid bodies and pancreatic progenitor PDX1+Ins? cells.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 1, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jon Odorico, Xiaofang Xu
  • Publication number: 20140045931
    Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: THE HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Q. PING DOU, TAK-HANG CHAN, DAVID M. SMITH
  • Publication number: 20120282353
    Abstract: The present invention generally relates to the modulation of hypoxia-inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.
    Type: Application
    Filed: March 26, 2012
    Publication date: November 8, 2012
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Mark B. Roth, Mark Budde
  • Patent number: 8216842
    Abstract: The present invention provides methods of enhancing hybridoma fusion efficiencies through cell synchronization of the fusion partners, in order to aid in production of antibodies.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: July 10, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Jill Giles-Komar, Michael Rycyzyn, Gregory Bannish
  • Publication number: 20120121557
    Abstract: The present invention provides methods for inducing division of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to repair heart tissue damaged by, for example, myocardial ischemia, hypoxia, stroke, myocardial infarction or chronic ischemic heart disease in vivo. In addition, the methods of the invention can be used to induce heart muscle cells to divide in vitro, in vivo and/or ex vivo, which can then be used in heart tissue repair.
    Type: Application
    Filed: July 20, 2010
    Publication date: May 17, 2012
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventor: Bernhard Kuhn
  • Patent number: 8158420
    Abstract: The present invention provides methods for regulating the growth and/or survival of tumor cells and stem cells by modulating the expression or function of ATF5. The present invention also provides methods for promoting or suppressing differentiation of stem/progenitor cells, for producing differentiated cells and for isolating/purifying differentiated cells, including neural cells. Also provided are differentiated cells, cell populations and transgenic animals comprising same and uses of same. The present invention further provides methods for treating nervous tissue degeneration and for identifying an agent for use in treating nervous tissue degeneration. Methods for promoting apoptosis in neoplastic cells and for treating or preventing tumors, and identifying agents for use in treating or preventing tumors are also provided by the present invention. The present invention further provides methods for identifying agents that inhibit ATF5, agents identified by these methods.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: April 17, 2012
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Lloyd A Greene, James M Angelastro
  • Patent number: 8153424
    Abstract: A method of differentiating embryonic stem cells into ventral spinal progenitor cells is disclosed. In one embodiment, the invention comprises culturing a population of cells comprising a majority of cells that are characterized by an early rosette morphology and are Sox1?/Pax6+ in the presence of retinoic acid, wherein the cells express Hoxb4, but not Otx2 or Bf1.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: April 10, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Xue-Jun Li
  • Patent number: 8119405
    Abstract: Disclosed are methods and pharmaceutical compositions for inducing pancreatic hormone production.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: February 21, 2012
    Inventor: Sarah Ferber
  • Patent number: 8084257
    Abstract: This invention relates to methods for distinguishing and sorting cells. In particular it includes methods for distinguishing and sorting post-mitotic and post-meiotic daughter cells into two classes according to differential cellular features. Labeling, tagging, or marking of the cells' chromatin proteins, RNA, or DNA may assist in distinguishing the daughter cells. In some embodiments, two cell classes may be studied and the cells' proteins, glycoproteins, and RNA may be identified and subset. Information from these subsets may then be used to distinguish and sort the two classes of cells from similar tissues according to protein, glycoprotein, and RNA makeup.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: December 27, 2011
    Inventor: Thomas M. Donndelinger
  • Patent number: 7989178
    Abstract: A system combining a clonogenic differentiation assay with an instrument-based ATP bioluminescence proliferation assay to produce a standardized colony-forming stem and progenitor cell potency assay is provided.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: August 2, 2011
    Assignee: Hemogenix, Inc.
    Inventor: Ivan N. Rich
  • Publication number: 20110046092
    Abstract: A method of preparing neural precursor cells by exposing pluripotent stem cells or neural stem cells to a differentiation agent. The agent is a pyridine analog, which in preferred embodiments is a phenylethynyl-substituted or phenylazo-substituted pyridine. In other embodiments, a method of enhancing neural precursor cell survival is provided in which the survival is enhanced by exposure to the pyridine analog. In further embodiments, a method of preparing neuronal cells is provided in which pluripotent or neural stem cells exposed to the pyridine analog are then incubated without the pyridine analog, resulting in differentiation into neurons, astrocytes and oligodendrocytes. These methods may be used in toxicological screens, e.g., to evaluate the neurotoxicity of a test compound.
    Type: Application
    Filed: December 11, 2008
    Publication date: February 24, 2011
    Applicant: Research Development Foundation
    Inventors: David M. Suter, Olivier Preynat-Seauve, Karl-Heinz Krause
  • Patent number: 7883861
    Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: February 8, 2011
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7829332
    Abstract: The present invention relates to a method of inhibiting differentiation of a population of neural stem cells by contacting a purinergic receptor agonist and a population of neural stem cells under conditions effective to inhibit differentiation of the population of neural stem cells. Another aspect of the present invention relates to a method of producing neurons and/or glial cells from a population of neural stem cells by culturing a population of neural stem cells with a purinergic receptor antagonist under conditions effective to cause the neural stem cells to differentiate into neurons and/or glial cells. The purinergic receptor agonist can also be used in a method of inducing proliferation and self-renewal of neural stem cells in a subject and a method of treating a neurological disease or neurodegenerative condition in a subject. The purinergic receptor antagonist can also be used in treating a neoplastic disease of the brain or spinal cord in a subject.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: November 9, 2010
    Assignees: Cornell Research Foundation, Inc., New York Medical College
    Inventors: Steven A. Goldman, Maiken Nedergaard, Jane Lin
  • Patent number: 7732201
    Abstract: A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: June 8, 2010
    Assignee: The Regents of the University of California
    Inventors: Fred H. Gage, Jasodhara Ray
  • Publication number: 20100074875
    Abstract: A use of a composition comprising umbilical cord blood-derived mesenchymal stem cells for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells is provided, the composition being effective for the treatment of nerve injury diseases.
    Type: Application
    Filed: November 29, 2007
    Publication date: March 25, 2010
    Applicant: Medipost Co., Ltd.
    Inventors: Wonil Oh, Yoon-Sun Yang, Jong Wook Chang, Soo Jin Choi, Ju-Yeon Kim
  • Patent number: 7682799
    Abstract: This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: March 23, 2010
    Assignee: University of Massachusetts
    Inventors: Stephen J. Doxsey, Chun-Ting Chen
  • Patent number: 7666615
    Abstract: The present invention relates generally to assays, methods, and kits that provide reagent mixes and instructions for determining the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: February 23, 2010
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7456154
    Abstract: The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: November 25, 2008
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Hermona Soreq, Jackilynne Seidman, legal representative, Tama Evron, Shlomo Seidman
  • Patent number: 7354730
    Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: April 8, 2008
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7354729
    Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: April 8, 2008
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7335811
    Abstract: Methods for collecting cells in M phase or G1 phase, by which the percentage of M phase or G1 phase cells is higher than that attained by the conventional methods are disclosed.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: February 26, 2008
    Assignee: The Japanese Research Association for Animal Embryo Transfer Technology c/o Livestock Improvement Association of Japan
    Inventors: Manami Urakawa, Yoshito Aoyagi
  • Patent number: 7030292
    Abstract: A method of producing a homogenous population of homozygous stem (HS) cells pre-selected for immunotype and/or genotype from donor cells is described herein. The invention relates to methods of using immunohistocompatible HS cells for diagnosis, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, traumatic injuries and cancer. The invention further relates to methods for using histocompatible HS stem cells pre-selected for a non-disease genotype for prophylactic and therapeutic intervention including, but not limited to, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, and cancer.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: April 18, 2006
    Assignee: Stemron, Inc.
    Inventors: Wen Liang Yan, Steve Chien-Wen Huang, Minh-Thanh Nguyen, Huan (Helen) Lin, Jingqi Lei, Ruchi Khanna
  • Patent number: 6969609
    Abstract: The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of them costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater that the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+and CD8+T cells.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: November 29, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Serivces
    Inventors: Jeffrey Schlom, James Hodge, Dennis Panicali
  • Patent number: 6867040
    Abstract: Apparatus and methods are directed to a perfusion culture system in which a rotating bioreactor is used to grow cells in a liquid culture medium, while these cells are attached to an adhesive-treated porous surface. As a result of this arrangement and its rotation, the attached cells divide, with one cell remaining attached to the substrate, while the other cell, a newborn cell is released. These newborn cells are of approximately the same age, that are collected upon leaving the bioreactor. The populations of newborn cells collected are of synchronous and are minimally, if at all, disturbed metabolically.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: March 15, 2005
    Inventors: Charles E. Helmstetter, Maureen Thornton, Steve Gonda
  • Patent number: 6753181
    Abstract: The invention is directed to methods for producing a decellularized organ or part of an organ. A decellularized organ is produced using an isolated organ mechanically agitated to remove cellular membranes surrounding the isolated organ without destroying the interstitial structure of the organ. After the cellular membrane is removed, the isolated organ is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the organ. A washing fluid is used to remove the solubilized components, leaving behind a decellularized organ.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: June 22, 2004
    Assignee: Children's Medical Center Corporation
    Inventor: Anthony Atala
  • Patent number: 6667175
    Abstract: This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.
    Type: Grant
    Filed: June 15, 1999
    Date of Patent: December 23, 2003
    Assignee: The Trustees of Columbia University
    Inventor: Nicole Suciu-Foca
  • Publication number: 20030215945
    Abstract: The invention is directed to methods for producing a decellularized organ or part of an organ. A decellularized organ is produced using an isolated organ mechanically agitated to remove cellular membranes surrounding the isolated organ without destroying the interstitial structure of the organ. After the cellular membrane is removed, the isolated organ is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the organ. A washing fluid is used to remove the solubilized components, leaving behind a decellularized organ.
    Type: Application
    Filed: June 18, 2003
    Publication date: November 20, 2003
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventor: Anthony Atala
  • Patent number: 6525243
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: February 25, 2003
    Assignees: Roslin Institute, The Minister of Agricultural, Fisheries and Food, Biotechnology & Biological Sciences Research Council
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Patent number: 6465251
    Abstract: We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B cells can be obtained from peripheral blood in large numbers. These cells can be activated in vitro by coculture with CD40L (CD40-B cells) and an immunosuppressive agent such as cyclosporin A. They can expanded up to 1×103 to 1×104 fold in 2 weeks or 1×105 to 1×106 fold in 2 months. We demonstrate these cells are most efficient APCs comparable to DCs in stimulating allogeneic CD4+ CD45RA+, CD4+ CD45RO+, and CD8+ T cells. In contrast to DCs, CD40-B cells are fully functional even in the presence of immunosuppressive cytokines such as IL-10 and TGF&bgr;.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: October 15, 2002
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Joachim L. Schultze, Gordon J. Freeman, John G. Gribben, Lee M. Nadler
  • Publication number: 20020119568
    Abstract: The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and stimulate cells that maximizes stimulation and/or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and/or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and/or receptor signaling enhancement.
    Type: Application
    Filed: September 20, 2001
    Publication date: August 29, 2002
    Inventors: Ronald Berenson, Che Law, Mark Bonyhadi, Narinder Saund, Stewart Craig, Alan Hardwick, Dale Kalamasz, David McMillen
  • Patent number: 6376244
    Abstract: The invention is directed to methods for producing a decellularized organ or part of an organ. A decellularized organ is produced using an isolated organ mechanically agitated to remove cellular membranes surrounding the isolated organ without destroying the interstitial structure of the organ. After the cellular membrane is removed, the isolated organ is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the organ. A washing fluid is used to remove the solubilized components, leaving behind a decellularized organ.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: April 23, 2002
    Assignee: Children's Medical Center Corporation
    Inventor: Anthony Atala
  • Patent number: 6290951
    Abstract: A first substance (such as the peptide aldehydes LLnL and LVP) inhibits the function of intracellular proteasome. A second substance (such as ranpirnase) inhibits intracellular protein synthesis or increases intracellular expression of a cyclin-dependent kinase (CDK) inhibitor. Both substances are administered in such a manner that the effects thereof are coincident. The cell cycle of affected tumor cells is therefore arrested and the cells die of apoptosis.
    Type: Grant
    Filed: August 1, 1998
    Date of Patent: September 18, 2001
    Assignee: Alfacell Corporation
    Inventor: Stanislaw M. Mikulski
  • Patent number: 6248541
    Abstract: Described herein are methods for obtaining from an initial population of cells a plurality of subpopulations of cells having a similar density by growing samples from the initial population in medium having a limiting nutrient. Also provided are methods for using such subpopulation of cells to identify members of an initial population, either spontaneously occurring or induced by mutagenesis, having altered and/or preferred phenotypes.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: June 19, 2001
    Assignee: Genencor International, Inc.
    Inventor: Volker Schellenberger
  • Patent number: 6225044
    Abstract: A method is disclosed for gene transfer into a culture of primitive stem cells which comprises a prestimulation step of adding a blocking agent to block at least one inhibitor of a cell cycle of said primitive stem cells. The prestimulation is time-limited for a period of less than approximately 36 hours so that said culture of primitive stem cells retains hematopoietic potential.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: May 1, 2001
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Antoinette Klein, Jacques Hatzfeld
  • Patent number: 6143560
    Abstract: The present invention relates to a method of synchronizing epithelial cells into G.sub.0 phase, more specifically, a method of synchronizing epithelial cells into G.sub.0 phase characterized by culturing the cells in a synthetic medium for 5 days or more, wherein said synthetic medium is a medium with the lowered concentration of bovine fetal serum 5% or less and said epithelial cells is bovine mammary gland cells. Further, the present invention relates to a method of culturing cells characterized by using G.sub.0 phase synchronized cells obtained by the present invention, and a method of screening a related to differentiation and/or maturation of said cells by using G.sub.0 phase synchronized cells. The present invention is useful for easily synchronizing epithelial cells into G.sub.0 phase and for screening a factor related to differentiation and/or maturation of epithelial cells.
    Type: Grant
    Filed: October 27, 1998
    Date of Patent: November 7, 2000
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Mio Imamura, Yasuharu Itagaki, Morimasa Tanimoto
  • Patent number: 6118044
    Abstract: Transgenic mice which constitutively express an antibody-type molecule encoded by the transgene and which has an IgE heavy chain constant region and is specific for a pre-defined antigen, provide an allergic reaction to that antigen without prior sensitization and are useful as allergy models.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: September 12, 2000
    Assignees: Sankyo Company, Limited, The Tokyo Metropolitan Institute of Medical Science
    Inventors: Hajime Karasuyama, Hiromichi Yonekawa, Choji Taya, Kunie Matsuoka
  • Patent number: 6020146
    Abstract: The present invention is directed to an in vitro method for detecting the presence of carcinogenic agents.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: February 1, 2000
    Assignee: The Research Foundation State University of New York
    Inventor: Bozidar Djordjevic
  • Patent number: 5837544
    Abstract: The present invention is directed to novel chimeric proliferation receptor proteins and DNA sequences encoding these proteins where the chimeric proteins are characterized in three general categories. In one category, the novel chimeric proteins comprise at least three domains, namely, an extracellular inducer-responsive clustering domain capable of binding an extracellular inducer that transmits a signal to a proliferation signaling domain, a transmembrane domain and a proliferation signaling domain that signals a host cell to divide. In the second category, the novel chimeric proteins comprise at least two domains, namely, an intracellular inducer-responsive clustering domain capable of binding an intracellular inducer and a proliferation signaling domain that signals the cell to divide.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: Cell Genesys, Inc.
    Inventors: Daniel J. Capon, Huan Tian, Douglas H. Smith, Genine A. Winslow, Miriam Siekevitz
  • Patent number: 5674750
    Abstract: A system is provided for selective clonogenic expansion of relatively undifferentiated cells, including (a) a tube containing a plurality of beads of a size which permits a plurality of the undifferentiated cells to grow thereon, the beads bearing on their surfaces a selective binding molecule which binds to a surface antigen present on the relatively undifferentiated cells, wherein the antigen is not present on the surfaces of the relatively differentiated cells; (b) means for continuously providing nutrients to the relatively undifferentiated cells growing on the beads, wherein the nutrients are delivered via a fluid which flows through the tube and past the beads; and (c) means for continuously harvesting the relatively undifferentiated cells downstream of the beads.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: October 7, 1997
    Assignee: t. Breeders
    Inventors: Morey Kraus, Jill Friberg